Abstract

BackgroundThe effectiveness of the switch when the first anti-TNF failure in patients with rheumatoid arthritis has been demonstrated in multiple studies. But what is more effective, if you make the...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
AB0495 Functional outcome in response to treatment with dmards compared to anti-TNF agents in a cohort with rheumatoid arthritis
D.L Scott ... B Kirkham
Annals of the Rheumatic Diseases | VOL. 71
D.L Scott, et. al.D.L Scott ... B Kirkham
01 Jun 2013
Is current smoking status and its relationship to anti-cyclic citrullinated peptide antibodies a predictor of worse response to biological therapies in rheumatoid arthritis patients?
V Torrente-Segarra ... S Al-Emadi
Scandinavian Journal of Rheumatology | VOL. 47
V Torrente-Segarra, et. al.V Torrente-Segarra ... S Al-Emadi
23 Apr 2018
AB0403 Dose Optimization of Biological Therapies in Rheumatoid Arthritis in Clinical Practice
L Sala ... A Morell
Annals of the Rheumatic Diseases | VOL. 73
L Sala, et. al.L Sala ... A Morell
01 Jun 2014
Drug survival of second biological DMARD therapy in patients with rheumatoid arthritis: a retrospective non-interventional cohort analysis
Sze Chim Lee ... Istvan Majer
BMC Musculoskeletal Disorders | VOL. 18
Sze Chim Lee, et. al.Sze Chim Lee ... Istvan Majer
02 Aug 2017
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers